ISFA Vienna 2011
8th International Society for Apheresis Congress
3. Wiener Aphereseseminar (Educational Program)
September 14th – 17th
University Hospital, Vienna - Austria

www.nephrologie.at
Congress Invitation – Letter from the President

To all people interested in apheresis

On behalf of the International Society for Apheresis (ISFA) it is my great pleasure to invite you to actively participate in our upcoming congress to be held in Vienna, September 14th–17th, 2011.

We are grateful to Dr. Derfler and his colleagues for taking over the task to organize ISFA’s 8th international congress. The congress will feature a great opportunity for you to update your knowledge base on apheresis and to meet and interact with leading clinicians and researchers from around the world. For beginners and allied health professionals there will be an Educational Program that will provide a comprehensive insight into the apheresis field. For the first time ISFA will honor best posters for specific topics immediately after the poster sessions that will be guided by experienced apheresis experts.

September is the perfect time to visit Vienna. The capital of Austria is located in the heart of Europe and is easily accessible by all kinds of transportation. It is a fascinating city that has preserved it’s rich history and culture you can sense around any corner. Together with the typical charm of the local people this characteristic mixture makes Vienna so unique.

Mark the date in your calendar and plan to join us in Vienna next year. It is my personal belief that our next congress will provide an exciting and productive atmosphere for all attendees allowing everyone to take home new insights and unforgettable memories.

Wolfgang Ramlow, M.D.
President ISFA 2009–2011

Premium Sponsors

Fresenius Medical Care
Miltenyi Biotec

ISFA Vienna 2011
www.nephrologie.at
Dear Colleagues, dear Friends!

On behalf of the local organizing team of the ISFA it is our pleasure and privilege to invite you to participate at the 8th ISFA Congress to be performed in Vienna from September 14th to September 17th, 2011.

Vienna with its great scientific and cultural heritage and a centuries old tradition of hosting people of various cultures certainly is predestined for organizing the ISFA Congress 2011. Located in the heart of Europe Vienna also provides unique possibilities to explore Austria and other eastern as well as western countries of Europe.

The ISFA congress will be organized together with several other societies dedicated to extracorporeal treatment modalities. This cooperation of various scientific communities will promote an interdisciplinary exchange of ideas and experience, an integration of basic research and clinical medicine. Furthermore, a special educational program (including the “3. Wiener Aphereseseminar”) will be offered both for clinical scientist and for nurses in particular.

The congress will be located at the hospital of the Medical University of Vienna, which is easily accessible from all parts of the city by underground.

Present day Vienna is a cosmopolitan, dynamic city with a booming cultural and economic life. With its rich architecture, its famous opera house, numerous museums, the “Heurigen” wine taverns, an acclaimed Central European “fusion cuisine”, Vienna can offer all participant of the ISFA Congress not only a high class scientific and educational program but also an extraordinary ambiance where you can relax, meet old and make new friends and exchange ideas.

We are cordially inviting all of you to the 8th ISFA Congress in Vienna, Austria in 2011.

Prof. Kurt Derfler – President of the ISFA 2011 Congress
Prof. Wilfred Druml – Vice-President of the ISFA 2011 Congress
Prof. Sabine Schmaldienst – Vice-President of the ISFA 2011 Congress
Prof. Alice Schmidt – Congress Secretary
Special Joint Organizing Committee

Derfler Kurt (Austria)  Congress President
Druml Wilfred (Austria)  Vice-President of the ISFA congress
Schmaldienst Sabine (Austria)  Vice-President of the ISFA congress
Schmidt Alice (Austria)  Congress Secretary
Ramlow Wolfgang (Germany)  President ISFA 2009–2011
Klinkmann Horst (Germany)  Honorary Congress President
Nosé Yukihiko (USA)  Honorary Congress President

ISFA Officers, the ISFA Board of Trustees and Members of the Scientific Programme Committee ISFA Congress 14th–17th September 2011

Ramlow Wolfgang (Germany)  President ISFA 2009–2011
Tani Tohru (Japan)  President elect
Siami Ghodrat A. (USA)  Immediate Past-President
Figueroa Mario (Argentina)  Vice President
Tsuda Hiroshi (Japan)  Vice President
Derfler Kurt (Austria)  Vice President
Endo Yoshihiro (Japan)  Secretary Treasurer
Akizawa Tadao (Japan)  Editor in Chief: Ther Apheresis and Dialysis
Klinkmann Jens (Germany)  Regional Officer Europe
Kong Deling (PRC)  Regional Officer Pan Pacific
Lin Kuo-Juei (ROC)  Regional Officer Pan Pacific
Yonekawa Motoki (Japan)  Regional Officer Pan Pacific

America
Ash S.R. (USA)  Hadsell A.T. (USA)  Ivanovitch P. (USA)
Kaplan A. (USA)  Khatri B.O. (USA)  Koo A. (USA)
Rock G. (Canada)  Siami F.S. (USA)  Torloni A.S. (USA)

Pan-Pacific, Middle East and Asia
Al-Humaidan Hind A. (Saudi Arabia)  Chiu H.C. (ROC)  Fukunaga K. (Japan)
Han K.S. (Korea)  Koga N. (Japan)  Kostner K. (Australia)
Lumlertgul D. (Thailand)  Matsumoto T. (Japan)  Mihesmima M. (Japan)
Nampoory N. (Kuwait)  Sawada K. (Japan)  Shibuya N. (Japan)
Shoji H. (Japan)  Suzuki Y. (Japan)  Xue J. (ROC)
Yamamoto T. (Japan)  Yonekawa M. (Japan)

Europe
Aringer M. (Germany)  Baurmeister U. (Germany)  Biesenbach P. (Austria)
Böhmig G. (Austria)  Emmerich J. (Germany)  Falkenhagen D. (Austria)
Höcker P. (Austria)  Julius U. (Germany)  Klingel R. (Germany)
Klinkmann J. (Germany)  Knobler R. (Austria)  Leitner G. (Austria)
Mansouri B. (Switzerland)  Moog R. (Germany)  Pokrovsky S.N. (Russia)
Ponikvar R. (Slovenia)  Ramunni A. (Italy)  Rech J. (Germany)
Schuff-Werner P. (Germany)  Sikole A. (Macedonia)  Staudt A. (Germany)
Stefanutti C. (Italy)  Stegmayr B. (Sweden)  Stumvoll G. (Austria)
Szpirt W. (Denmark)  Valenta R. (Austria)  Vogt A. (Germany)
Witt A. (Austria)  Worel N. (Austria)  Zillikens D. (Germany)

ISFA Vienna 2011

www.nephrologie.at
**PRELIMINARY MAIN TOPICS of ISFA 2011**

**Lipoprotein (LDL/Lp(a)) Apheresis**
- Different devices (Adsorption, Precipitation, Double Filtration; Single use versus reusable systems?)
- Long term outcome of LDL-apheresis in homozygous and heterozygous familial hypercholesterolaemia
- LDL-apheresis in children!
- LDL-apheresis and additional medical treatment in children with homozygous familial hypercholesterolaemia (FH)
- Additional medical treatment in adult patients with FH on LDL-apheresis
- Hemorheological investigations in LDL-apheresis and related treatment options
- Lp(a) and atherosclerotic vascular disease: Which patients are candidates for lipoprotein apheresis?
- Results on Lp(a) removal by different treatment modalities?
- Concomitant medical treatment for secondary prevention of cardiovascular disease in patients suffering from elevated Lp(a)
- Strategies to identify high-risk atherosclerotic patients as candidates for lipoprotein apheresis therapy

**Apheresis Therapy in Rheumatic disease**
- **Plenary lecture:** Autoantibodies in systemic rheumatic disease.
- Immunoadsorption (IAS) in Lupus nephritis (including the long-term follow up of these patients)
- IAS in anti-phospholipid – antibody syndrome
- IAS in dermatomyositis and polymyositis (a prospective, multicenter study protocol will be presented at the stock exchange at the congress)
- IAS and plasma exchange in systemic vasculitis?
- Additional immunosuppressive treatment in patients with rheumatic diseases on IAS
- IAS in the Goodpasture Syndrome; Wegener’s disease?
- Plasma exchange in ANCA associated vasculitis

**The Status of Apheresis Therapy in Neurological Disease**
- Multiple Sclerosis
- Neuromyelitis optica
- Myasthenia gravis
- CIDP

**Cytapheresis**
- State of the art lecture: Cytapheresis in ulcerative colitis
- Long-term cytapheresis therapy in refractory ulcerative colitis with acute flare
- Efficacy and safety of cytapheresis treatment in patients with ulcerative colitis: the post marketing surveillance of more than 600 patients in Japan
- Laboratory test: predictive markers of response for cytapheresis treatment in active ulcerative colitis
- Cytapheresis in Crohn’s disease
- Cytapheresis in rheumatic diseases
- Cytapheresis in skin diseases
- Platelets – a new target for cytapheresis?

**Photopheresis**
- **Plenary lecture:** Over two decades of extracorporeal photopheresis – state of the art lecture
- Extracorporeal photopheresis: mechanism of action
- Photopheresis in graft versus host disease
- The role of photopheresis in lung transplantation
- Experience of photopheresis in cutaneous T-cell lymphoma
- Extracorporeal Photopheresis in cutaneous T-cell lymphoma: the British experience

**Apheresis Treatment in Dermatological Indications**
- **Plenary lecture:** Targeting IgE antibodies: A universal therapy for allergy?
- IgE-apheresis for treatment of patients with hypersensitivity?
- Immunoadsorption and Omalizumab in serious atopic dermatitis and allergic asthma bronchialis
- Immunoadsorption in autoimmune bullous diseases

**ISFA Vienna 2011**

**www.nephrologie.at**
ABO incompatible kidney transplantation
ABO-incompatible kidney transplantation – the Japanese experience
ABO-incompatible kidney transplantation – the Stockholm experience
ABO-incompatible kidney transplantation – the German experience
ABO-incompatible kidney transplantation – the Austrian experience

Immunoadsorption in solid organ transplantation / Apheresis in HLA-incompatible transplantation

Plenary session: Antibody-mediated transplant rejection
Treatment options for antibody-mediated rejection
Positive cross-match living donor kidney transplantation
Positive cross-match deceased donor kidney transplantation
Apheresis in thoracic organ transplantation

Therapeutic Apheresis in TTP (Thrombotic thrombocytopenic purpura): Any new options for TTP and HUS (Hemolytic Uremic Syndrome)
Plasma Exchange, Immunoadsorption, Rituximab and New Drugs?
Clinical Trials in TTP / HUS: New Guidelines available?
New options for drug treatment in TTP?
Rituximab in TTP – The STAR-Trial – terminated due to serious side effects?

Concomitant Drug Treatment in Apheresis / Plasma Exchange Therapy
Immunoglobulins (IvIg)
Cytotoxic drug treatment / Cyclophosphamide, Cyclosporine A, Everolimus, Sirolimus, Mycophenolate Mofetil, Azathioprine
Rituximab / Abatacept and New Drugs? Benefit and serious side effects?

Extracorporeal Treatment Modalities Mixed Session
Immunoadsorption in Pulmonary Arterial Hypertension (PAH)
Immunoadsorption in Thrombangitis Obliterans / auto-AB and results of a pilot study
Immunoadsorption in hemophiliacs with coagulation factor inhibitors
Double filtration plasmapheresis in chronic hepatitis C patients

Extracorporeal Treatment Options in Sepsis
Apheresis therapy in septic patients – The Japanese experience
Bioreactor therapy – a new approach to treat septic patients
Nanoparticles in sepsis therapy

Extracorporeal Liver Replacement Therapy
The MARS versus the PROMETHEUS System
Detailed analysis of the HELIOS Trial
Detailed presentation of the HRS-Study
Extracorporeal liver replacement therapy for treatment of severe pruritus due to advanced liver disease (A preliminary study protocol will be presented at the ISFA-congress stock exchange)

Approval and Reimbursement
National particularities vs. international harmonization

Apheresis Registries
Do apheresis registries really help treating our patients better?
The importance of prospective data collection for approval and reimbursement?

Clinical Trials Section
Current major trials – designs and expectations
Patient selection
Recent trials – outcome and lessons to be learned

Mode of Action of Immune Apheresis
Immunomodulation vs. Immunodepletion
The role of immunocompetent cells
Modification of immunocompetent cells
The role of AAB in certain diseases
REGISTRATION (online: www.nephrologie.at)

There are significant savings for early conference registration. For those registered by June 17\textsuperscript{th} 2011, there will be a reduced fee. For combined company registration a reduced conference fee is provided. ISFA members receive a € 100 discount. The registration fee includes the costs of the congress, welcome reception, coffee breaks, luncheons and the social evening event at the famous Rathaus of the city of Vienna. Furthermore a supplement of Therapeutic Apheresis and Dialysis with all the abstracts will be provided. Fees may be paid by credit card or cash.

ISFA congress and Educational Session (3. Wiener Aphereseseminar – German Language Symposium)

<table>
<thead>
<tr>
<th></th>
<th>Members</th>
<th>Non Members</th>
</tr>
</thead>
<tbody>
<tr>
<td>For the complete congress (Early registration)</td>
<td>€ 300</td>
<td>€ 400</td>
</tr>
<tr>
<td>For the complete congress (Late registration)</td>
<td>€ 400</td>
<td>€ 500</td>
</tr>
<tr>
<td>One-day ticket</td>
<td>€ 150</td>
<td>€ 175</td>
</tr>
<tr>
<td>Nurses</td>
<td>€ 150</td>
<td>€ 175</td>
</tr>
<tr>
<td>Students</td>
<td>€ 50</td>
<td>€ 50</td>
</tr>
<tr>
<td>Company registration (N ≥ 10)</td>
<td>€ 250/person</td>
<td>€ 350/person</td>
</tr>
<tr>
<td>Company registration (N ≥ 15)</td>
<td>€ 225/person</td>
<td>€ 325/person</td>
</tr>
</tbody>
</table>

Educational Session (3. Wiener Aphereseseminar – German Language Symposium)

<table>
<thead>
<tr>
<th></th>
<th>Members</th>
<th>Non Members</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total educational session</td>
<td>€ 150</td>
<td>€ 175</td>
</tr>
<tr>
<td>Nurses</td>
<td>€ 100</td>
<td>€ 125</td>
</tr>
<tr>
<td>Students</td>
<td>€ 30</td>
<td>€ 30</td>
</tr>
<tr>
<td>Company registration (N ≥ 10)</td>
<td>€ 125</td>
<td>€ 150</td>
</tr>
<tr>
<td>Company registration (N ≥ 15)</td>
<td>€ 100</td>
<td>€ 125</td>
</tr>
</tbody>
</table>

A certificate of attendance will be provided at the registration counter, both for the ISFA congress and the educational session (3. Wiener Aphereseseminar).

Discount opportunities for CORPORATE MEMBERS of ISFA
Rental fee for industrial space 20% (regular € 400/m\textsuperscript{2}).
Full registration fee waived for two company representatives.

Scientific Secretariat ISFA Vienna 2011
Prof. Sabine Schmaldienst, Prof. Alice Schmidt, Prof. Kurt Derfler
Medical University of Vienna
Dept. of Medicine III, Div. of Nephrology and Dialysis
Währinger Gürtel 18-20, A-1090 Vienna, Austria
Phone: +43 1 40400 4400
E-Mail: apheresewien@meduniwien.ac.at

Organizing Secretariat
Kuoni Destination Management Austria
Lerchenfelder Gürtel 43, A-1160 Vienna, Austria
Phone: +43 1 319 76 90-57, Fax: +43 1 319 11 80
E-Mail: ISFA2011@at.kuoni.com

Exhibition & Sponsoring
MAW – Medizinische Ausstellungs- und Werbegesellschaft
Freyung 6/3, A-1010 Vienna, Austria
Phone: +43 1 536 63-35, Fax: +43 1 535 60 16
E-Mail: maw@media.co.at

Location
The conference will be held at the General Hospital / AKH
Währinger Gürtel 18-20, A-1090 Vienna, Austria

Hotel Accommodation and Social Program
For Details regarding hotel accommodation please visit our congress webpage.